Hoenen Thomas, Groseth Allison, Falzarano Darryl, Feldmann Heinz
Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington St., Winnipeg, MB R3E 3R2, Canada.
Trends Mol Med. 2006 May;12(5):206-15. doi: 10.1016/j.molmed.2006.03.006. Epub 2006 Apr 17.
Ebola virus (EBOV) causes severe haemorrhagic fever leading to up to 90% lethality. Increasingly frequent outbreaks and the placement of EBOV in the category A list of potential biothreat agents have boosted interest in this virus. Furthermore, development of new technologies (e.g. reverse genetics systems) and extensive studies on Ebola haemorrhagic fever (EHF) in animal models have substantially expanded the knowledge on the pathogenic mechanisms that underlie this disease. Two major factors in EBOV pathogenesis are the impairment of the immune response and vascular dysfunction. Here, we attempt to summarize the current knowledge on EBOV pathogenesis focusing on these two factors and on recent progress in the development of vaccines and potential therapeutics.
埃博拉病毒(EBOV)可引发严重出血热,致死率高达90%。疫情爆发日益频繁,且EBOV被列入A类潜在生物威胁病原体名单,这激发了人们对该病毒的兴趣。此外,新技术(如反向遗传学系统)的发展以及在动物模型中对埃博拉出血热(EHF)的广泛研究,极大地拓展了我们对该疾病致病机制的认识。EBOV发病机制中的两个主要因素是免疫反应受损和血管功能障碍。在此,我们试图围绕这两个因素以及疫苗和潜在治疗方法开发的最新进展,总结目前关于EBOV发病机制的知识。